1-3 of 3
Stefan Faderl
Close
Sort by
Journal Articles

Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AML

Clinical Trials & Observations
Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Stuart L. Goldberg, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet
Journal: Blood Advances
Blood Adv (2022) 6 (17): 4989–4993.
https://doi.org/10.1182/bloodadvances.2021006468
Published: 2022
Includes: Supplemental data
Journal Articles

Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses

Clinical Trials & Observations
Tara L. Lin, David A. Rizzieri, Daniel H. Ryan, Gary J. Schiller, Jonathan E. Kolitz, Geoffrey L. Uy, Donna E. Hogge, Scott R. Solomon, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes, Jeffrey E. Lancet
Journal: Blood Advances
Blood Adv (2021) 5 (6): 1719–1728.
https://doi.org/10.1182/bloodadvances.2020003510
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome

Clinical Trials & Observations
Je-Hwan Lee, Stefan Faderl, John M. Pagel, Chul Won Jung, Sung-Soo Yoon, Animesh D. Pardanani, Pamela S. Becker, Howard Lee, Jeongeun Choi, Kyoungjune Lee, Minkyoung Kim, Jorge E. Cortes
Journal: Blood Advances
Blood Adv (2020) 4 (9): 2032–2043.
https://doi.org/10.1182/bloodadvances.2019000757
Published: 2020
Includes: Supplemental data